About Aktis Oncology Inc
Expanding the breakthrough potential of targeted radiopharmaceuticals to large cancer patient populations.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Company type
- Public Company
- Company profile name
- Aktis Oncology
Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.
Business areas
- Health Care
- Oncology
- Biotechnology
- Life Science
On LinkedIn
- Followers
- 11,817
- People linked to this company
- 90
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
331,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.